Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TK1 | P04183 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34209 | 0.99 | POLB (0.63) | POLBTK1LMNATSHRALB | |
| SCHEMBL9201376 | 0.99 | POLB (0.63) | POLBTK1LMNATSHRALB | |
| SCHEMBL547923 | 0.87 | POLB (0.66) | POLBTK1 | |
| SCHEMBL10380716 | 0.87 | TK1 (0.58) | POLBTK1LMNATSHRALB | |
| SCHEMBL9229137 | 0.87 | TYMS (0.54) | LMNA | |
| SCHEMBL27677810 | 0.86 | POLB (0.57) | POLBTK1LMNATSHRALB | |
| SCHEMBL1360475 | 0.85 | TK1 (0.61) | POLBTK1LMNATSHRALB | |
| Thymidine Monophosphate SCHEMBL17075779 | 0.85 | POLB (0.74) | POLBTK1 | |
| Thymidine Monophosphate SCHEMBL9559854 | 0.83 | POLB (0.78) | POLBTK1 | |
| SCHEMBL17667452 | 0.83 | TK1 (0.68) | POLBTK1LMNATSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590683-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | Bristol-Myers Squibb Company (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240166675-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2024-05-23 | — | — | US | disclosed |
| WO-2024064638-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166675-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, NUDT1, NT5C3B | POLB 402/4885TK1 151/4885LMNA 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.